Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJayastu SenapatiESElizabeth J. ShpallNPNaveen Pemmaraju

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows cladribine and venetoclax improve outcomes in AML patients undergoing allogeneic stem cell transplantation, suggesting effective remission strategies.

Key Points

  • This research aims to analyze the survival outcomes and relapse patterns following allogeneic stem cell transplantation in patients with acute myeloid leukemia treated with cladribine and venetoclax.
  • Retrospective study of patients with newly diagnosed acute myeloid leukemia treated with cladribine-based regimens and followed by allogeneic stem cell transplantation.
  • Patients received either intensive chemotherapy or low-intensity therapy.
  • Survival outcomes, relapse patterns, and minimal residual disease status were analyzed.
  • 303 patients treated with cladribine-based therapy, 140 underwent allogeneic stem cell transplantation in first remission.
  • The 3-year relapse-free survival and overall survival for the cohort were 77% and 78%, respectively.
  • High rates of MRD negativity were observed prior to transplantation, with 78% achieving MRD negativity.

Cite This Study

Senapati et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e45fhttps://doi.org/10.1182/blood-2025-1630
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia2026 · 1 citations
  2. 2Cladribine (CLAD) + low-dose AraC (LDAC) + venetoclax (VEN) in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome: Real-world analysis from a large community-based oncology practice.2026
  3. 3Efficacy and safety of a new cladribine-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with relapsed or refractory acute myeloid leukemia2026
  4. 4Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial2025
  5. 5Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation2025